JBM  Vol.5 No.2 , February 2017
Equally Knocking on the Door of Medical Breakthroughs: Safety and Efficacy of a New Anti-Cancer Drug Pamica (PICNH2Ca) for Late Stage Cancer Patients
Abstract: The composition of Pamica (PICNH2Ca2) is dsRNA polyI:C, non-biotics amino compounds and CaCl2. It is the second generation noncytotoxic product of PICKCa (PIKA) adjuvant which was found effective in phase II clinical trial for PICKCa rabies vaccine and phase I trial for PICKCa hepatitis B vaccine in Singapore. With their knowledge and consent, cancer patients, regardless of their tumor types or performance status (ECOG above 5 or ECOG > 20), who were unresponsive to standard treatment, were treated free of charge with Pamica by injection or nasal spray. The primary results indicated that Pamica had no side effect except for a few cases of local pain in the site of injection and appeared to markedly improve cancer patients’ appetite, physical strength, quality of life and extended patients’ life for months and counting. These preliminary findings underlined promise of this potentially life-saving drug. In the hope of cooperating with the proper authorities, companies, and hospitals to benefit patients at the earliest opportunity, we share our findings in this paper.
Cite this paper: Lin, H. and Liu, F. (2017) Equally Knocking on the Door of Medical Breakthroughs: Safety and Efficacy of a New Anti-Cancer Drug Pamica (PICNH2Ca) for Late Stage Cancer Patients. Journal of Biosciences and Medicines, 5, 49-54. doi: 10.4236/jbm.2017.52005.

[1]   Lin, H.X., Gontier, C., Saron, M.-F. and Perrin, P. (1993) A New Immunostimulatory Complex (PICKCa) in Experimental Rabies: Antiviral and Adjuvant Effects. Archives of Virology, 131, 307-319.

[2]   (1993) State Intellectual Property Office of the P.R.C. Patent: CN93108562.7.

[3]   Lin, H.X., Li, L.T. and Zhang, Y. (2015) Comparison of dsRNA Adjuvants—PIC, PICLC, PIC12U and PICKCa®. Open Journal of Nature Science, 3, 127-136.

[4]   China Food and Drug Administration (2000) National Standard of Polyinosinic-Polycytidylic Acid Injection (PICKCa). WS1-XG-050-2000.

[5]   Lin, H.X. and Zhang, Y. (2015) Mechanisem of Action of PICKCa Adjuvant and Its Therapeutic Vaccines. Open Journal of Nature Science, 3, 70-80.

[6]   Lin, H.X., Xu, G.L., Wu, J., et al. (2016) The Effects Treated with PICKCa Rabies Vaccine to Mice and Beagle Dogs Infected Rabies Wild Viruses and Volunteers Immunized with PICKCa Rabies Vaccine. Chinese Journal of Experimental and Clinical Virology, 30, 37-40.

[7]   Shen, E., Li, L., Li, L., et al. (2007) PIKA as an Adjuvant Enhances Specific Humoral and Cellular Immune Responses Following the Vaccination of Mice with HBsAg plus PIKA. Cellular & Molecular Immunology, 4, 113-120.

[8]   Lau, Y.F., Tang, L.-H., Ooi, E.-E. and Subbarao, K. (2010) Activation of the Innate Immune System Provides Broad-Spectrum Protection against Influenza A Viruses with Pandemic Potential in Mice. Virology, 406, 80-87.

[9]   Lau, Y.-F., Tang, L.-H. and Ooi, E.-E. (2009) A TLR3 Ligand That Exhibits Potent Inhibition of Influenza Virus Replication and Has Strong Adjuvant Activity Has the Potential for Dual Applications in an Influenza Pandemic. Vaccine, 27, 1354-1364.

[10]   Tang, L.H., Lim, J.H., Kuah, L.F. and Lau, Y.F. (2014) Compete Protection against Lethal Challenge of Novel H7N9 Virus with Heterologous Inactevated H7 Vaccine in Mice. Vaccine, 32, 5375-5378.

[11]   (2016) State Intellectual Property Office of the P.R.C. Patent: PCT/CN2016/000544.